Open Access. Powered by Scholars. Published by Universities.®

Medicine and Health Sciences Commons

Open Access. Powered by Scholars. Published by Universities.®

Articles 1 - 15 of 15

Full-Text Articles in Medicine and Health Sciences

Hydroxyurea For Children With Sickle Cell Anemia In Sub-Saharan Africa, L. Tshilolo, G. Tomlinson, T. N. Williams, B. Santos, P. Olupot-Olupot, A. Lane, B. Aygun, S. E. Stuber, K. Mcelhinney, +59 Additional Authors Jan 2019

Hydroxyurea For Children With Sickle Cell Anemia In Sub-Saharan Africa, L. Tshilolo, G. Tomlinson, T. N. Williams, B. Santos, P. Olupot-Olupot, A. Lane, B. Aygun, S. E. Stuber, K. Mcelhinney, +59 Additional Authors

Journal Articles

No abstract provided.


The Role Of Objectively Measured, Altered Physical Activity Patterns For Body Mass Index Change During Inpatient Treatment In Female Patients With Anorexia Nervosa, C. S. Lehmann, T. Hofmann, U. Elbelt, M. Rose, C. U. Correll, A. Stengel, V. Haas Jan 2018

The Role Of Objectively Measured, Altered Physical Activity Patterns For Body Mass Index Change During Inpatient Treatment In Female Patients With Anorexia Nervosa, C. S. Lehmann, T. Hofmann, U. Elbelt, M. Rose, C. U. Correll, A. Stengel, V. Haas

Journal Articles

No abstract provided.


Racial And Ethnic Disparities In Diagnosis Of Chronic Medical Conditions In The Usa, E. J. Kim, T. Kim, J. Conigliaro, J. M. Liebschutz, M. K. Paasche-Orlow, A. D. Hanchate Jan 2018

Racial And Ethnic Disparities In Diagnosis Of Chronic Medical Conditions In The Usa, E. J. Kim, T. Kim, J. Conigliaro, J. M. Liebschutz, M. K. Paasche-Orlow, A. D. Hanchate

Journal Articles

No abstract provided.


A Collaborative, Network-Based Approach To Advance Women's Depression Research In The United States: Preliminary Findings, H. A. Flynn, C. Spino, C. Guille, K. M. Deligiannidis, P. Maki, J. Jahnke, K. L. Rosenblum, C. N. Epperson, S. J. Weiss Jan 2018

A Collaborative, Network-Based Approach To Advance Women's Depression Research In The United States: Preliminary Findings, H. A. Flynn, C. Spino, C. Guille, K. M. Deligiannidis, P. Maki, J. Jahnke, K. L. Rosenblum, C. N. Epperson, S. J. Weiss

Journal Articles

No abstract provided.


The Design And Evaluation Of The Comprehensive Hospitalist Assessment And Mentorship With Portfolios (Champ) Ultrasound Program, B. K. Mathews, K. Reierson, V. Khuong, A. Mehta, P. Miller, S. Koenig, M. Narasimhan Jan 2018

The Design And Evaluation Of The Comprehensive Hospitalist Assessment And Mentorship With Portfolios (Champ) Ultrasound Program, B. K. Mathews, K. Reierson, V. Khuong, A. Mehta, P. Miller, S. Koenig, M. Narasimhan

Journal Articles

No abstract provided.


The Comb Sign In Crohn's Ileocolitis, N. Adlakha, A. Swaminath Jan 2018

The Comb Sign In Crohn's Ileocolitis, N. Adlakha, A. Swaminath

Journal Articles

No abstract provided.


Medical Management With Or Without Interventional Therapy For Unruptured Brain Arteriovenous Malformations (Aruba): A Multicentre, Non-Blinded, Randomised Trial, J. P. Mohr, M. K. Parides, C. Stapf, E. Moquete, C. S. Moy, J. R. Overbey, R. A. S. Salman, E. Vicaut, R. Libman, Aruba Investigators Int, +12 Additional Authors Jan 2014

Medical Management With Or Without Interventional Therapy For Unruptured Brain Arteriovenous Malformations (Aruba): A Multicentre, Non-Blinded, Randomised Trial, J. P. Mohr, M. K. Parides, C. Stapf, E. Moquete, C. S. Moy, J. R. Overbey, R. A. S. Salman, E. Vicaut, R. Libman, Aruba Investigators Int, +12 Additional Authors

Journal Articles

Background The clinical benefit of preventive eradication of unruptured brain arteriovenous malformations remains uncertain. A Randomised trial of Unruptured Brain Arteriovenous malformations (ARUBA) aims to compare the risk of death and symptomatic stroke in patients with an unruptured brain arteriovenous malformation who are allocated to either medical management alone or medical management with interventional therapy. Methods Adult patients (>= 18 years) with an unruptured brain arteriovenous malformation were enrolled into this trial at 39 clinical sites in nine countries. Patients were randomised (by web-based system, in a 1: 1 ratio, with random permuted block design [block size 2, 4, or 6 ...


Twelve Or 30 Months Of Dual Antiplatelet Therapy After Drug-Eluting Stents, L. Mauri, D. J. Kereiakes, R. W. Yeh, P. Driscoll-Shempp, K. N. Garratt, D. P. Lee, T. K. Pow, P. V. Lee, M. J. Rinaldi, J. M. Massaro, +12 Additional Authors Jan 2014

Twelve Or 30 Months Of Dual Antiplatelet Therapy After Drug-Eluting Stents, L. Mauri, D. J. Kereiakes, R. W. Yeh, P. Driscoll-Shempp, K. N. Garratt, D. P. Lee, T. K. Pow, P. V. Lee, M. J. Rinaldi, J. M. Massaro, +12 Additional Authors

Journal Articles

BACKGROUND Dual antiplatelet therapy is recommended after coronary stenting to prevent thrombotic complications, yet the benefits and risks of treatment beyond 1 year are uncertain. METHODS Patients were enrolled after they had undergone a coronary stent procedure in which a drug-eluting stent was placed. After 12 months of treatment with a thienopyridine drug (clopidogrel or prasugrel) and aspirin, patients were randomly assigned to continue receiving thienopyridine treatment or to receive placebo for another 18 months; all patients continued receiving aspirin. The coprimary efficacy end points were stent thrombosis and major adverse cardiovascular and cerebrovascular events (a composite of death, myocardial ...


Resistance Mechanisms For The Bruton's Tyrosine Kinase Inhibitor Ibrutinib, J. A. Woyach, R. R. Furman, T. M. Liu, H. G. Ozer, M. Zapatka, A. S. Ruppert, L. Xue, D. H. H. Li, J. C. Barrientos, J. C. Byrd, +15 Additional Authors Jan 2014

Resistance Mechanisms For The Bruton's Tyrosine Kinase Inhibitor Ibrutinib, J. A. Woyach, R. R. Furman, T. M. Liu, H. G. Ozer, M. Zapatka, A. S. Ruppert, L. Xue, D. H. H. Li, J. C. Barrientos, J. C. Byrd, +15 Additional Authors

Journal Articles

BACKGROUND Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) and is effective in chronic lymphocytic leukemia (CLL). Resistance to irreversible kinase inhibitors and resistance associated with BTK inhibition have not been characterized. Although only a small proportion of patients have had a relapse during ibrutinib therapy, an understanding of resistance mechanisms is important. We evaluated patients with relapsed disease to identify mutations that may mediate ibrutinib resistance. METHODS We performed whole-exome sequencing at baseline and the time of relapse on samples from six patients with acquired resistance to ibrutinib therapy. We then performed functional analysis of identified ...


Idelalisib And Rituximab In Relapsed Chronic Lymphocytic Leukemia, R. R. Furman, J. P. Sharman, S. E. Coutre, B. D. Cheson, J. M. Pagel, P. Hillmen, J. C. Barrientos, A. D. Zelenetz, T. J. Kipps, S. M. O'Brien, +17 Additional Authors Jan 2014

Idelalisib And Rituximab In Relapsed Chronic Lymphocytic Leukemia, R. R. Furman, J. P. Sharman, S. E. Coutre, B. D. Cheson, J. M. Pagel, P. Hillmen, J. C. Barrientos, A. D. Zelenetz, T. J. Kipps, S. M. O'Brien, +17 Additional Authors

Journal Articles

BackgroundPatients with relapsed chronic lymphocytic leukemia (CLL) who have clinically significant coexisting medical conditions are less able to undergo standard chemotherapy. Effective therapies with acceptable side-effect profiles are needed for this patient population. MethodsIn this multicenter, randomized, double-blind, placebo-controlled, phase 3 study, we assessed the efficacy and safety of idelalisib, an oral inhibitor of the delta isoform of phosphatidylinositol 3-kinase, in combination with rituximab versus rituximab plus placebo. We randomly assigned 220 patients with decreased renal function, previous therapy-induced myelosuppression, or major coexisting illnesses to receive rituximab and either idelalisib (at a dose of 150 mg) or placebo twice daily ...


Ibrutinib Versus Ofatumumab In Previously Treated Chronic Lymphoid Leukemia, J. C. Byrd, J. R. Brown, S. O'Brien, J. C. Barrientos, N. E. Kay, N. M. Reddy, S. Coutre, C. S. Tam, S. P. Mulligan, P. Hillmen, +25 Additional Authors Jan 2014

Ibrutinib Versus Ofatumumab In Previously Treated Chronic Lymphoid Leukemia, J. C. Byrd, J. R. Brown, S. O'Brien, J. C. Barrientos, N. E. Kay, N. M. Reddy, S. Coutre, C. S. Tam, S. P. Mulligan, P. Hillmen, +25 Additional Authors

Journal Articles

Background In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are associated with a poor outcome. We evaluated the efficacy of ibrutinib, a covalent inhibitor of Bruton's tyrosine kinase, in patients at risk for a poor outcome. Methods In this multicenter, open-label, phase 3 study, we randomly assigned 391 patients with relapsed or refractory CLL or SLL to receive daily ibrutinib or the anti-CD20 antibody ofatumumab. The primary end point was the duration of progression-free survival, with the duration of overall survival and the overall ...


Glycated Hemoglobin Measurement And Prediction Of Cardiovascular Disease, E. Di Angelantonio, P. Gao, H. Khan, N. Wald, S. J. L. Bakker, P. H. Whincup, J. Kauhanen, J. T. Salonen, R. Dankner, J. Danesh, +66 Additional Authors Jan 2014

Glycated Hemoglobin Measurement And Prediction Of Cardiovascular Disease, E. Di Angelantonio, P. Gao, H. Khan, N. Wald, S. J. L. Bakker, P. H. Whincup, J. Kauhanen, J. T. Salonen, R. Dankner, J. Danesh, +66 Additional Authors

Journal Articles

IMPORTANCE The value of measuring levels of glycated hemoglobin (HbA(1c)) for the prediction of first cardiovascular events is uncertain. OBJECTIVE To determine whether adding information on HbA(1c) values to conventional cardiovascular risk factors is associated with improvement in prediction of cardiovascular disease (CVD) risk. DESIGN, SETTING, AND PARTICIPANTS Analysis of individual-participant data available from 73 prospective studies involving 294 998 participants without a known history of diabetes mellitus or CVD at the baseline assessment. MAIN OUTCOMES AND MEASURES Measures of risk discrimination for CVD outcomes (eg, C-index) and reclassification (eg, net reclassification improvement) of participants across predicted 10-year ...


Does A Glp-1 Receptor Agonist Change Glucose Tolerance In Patients Treated With Antipsychotic Medications? Design Of A Randomised, Double-Blinded, Placebo-Controlled Clinical Trial, J. R. Larsen, L. Vedtofte, J. J. Holst, P. Oturai, A. Kjaer, Christoph Correll, T. Vilsboll, A. Fink-Jensen Jan 2014

Does A Glp-1 Receptor Agonist Change Glucose Tolerance In Patients Treated With Antipsychotic Medications? Design Of A Randomised, Double-Blinded, Placebo-Controlled Clinical Trial, J. R. Larsen, L. Vedtofte, J. J. Holst, P. Oturai, A. Kjaer, Christoph Correll, T. Vilsboll, A. Fink-Jensen

Journal Articles

Background Metabolic disturbances, obesity and life-shortening cardiovascular morbidity are major clinical problems among patients with antipsychotic treatment. Especially two of the most efficacious antipsychotics, clozapine and olanzapine, cause weight gain and metabolic disturbances. Additionally, patients with schizophrenia-spectrum disorders not infrequently consume alcohol. Glucagon-like peptide-1 (GLP-1) has shown to improve glycaemic control and reduce alcohol intake among patients with type 2 diabetes. Objectives To investigate whether the beneficial effects of GLP-1 analogues on glycaemic control and alcohol intake, in patients with type 2 diabetes, can be extended to a population of pre-diabetic psychiatric patients receiving antipsychotic treatment. Methods and analysis Trial ...


Long-Term Exposure To Traffic-Related Air Pollution And Progression Of Carotid Artery Atherosclerosis: A Prospective Cohort Study, W. Q. Gan, R. W. Allen, M. Brauer, H. W. Davies, G. B. J. Mancini, S. A. Lear Jan 2014

Long-Term Exposure To Traffic-Related Air Pollution And Progression Of Carotid Artery Atherosclerosis: A Prospective Cohort Study, W. Q. Gan, R. W. Allen, M. Brauer, H. W. Davies, G. B. J. Mancini, S. A. Lear

Journal Articles

Objectives Epidemiological studies have demonstrated associations between long-term exposure to traffic-related air pollution and coronary heart disease (CHD). Atherosclerosis is the principal pathological process responsible for CHD events, but effects of traffic-related air pollution on progression of atherosclerosis are not clear. This study aimed to investigate associations between long-term exposure to traffic-related air pollution and progression of carotid artery atherosclerosis. Setting Healthy volunteers in metropolitan Vancouver, Canada. Participants and outcome measures 509 participants aged 30-65years were recruited and followed for approximately 5years. At baseline and end of follow-up, participants underwent carotid artery ultrasound examinations to assess atherosclerosis severity, including carotid ...


Antipsychotic Treatment For Children And Adolescents With Schizophrenia Spectrum Disorders: Protocol For A Network Meta-Analysis Of Randomised Trials, A. K. Pagsberg, S. Tarp, D. Glintborg, A. D. Stenstrom, A. Fink-Jensen, Christoph Correll, R. Christensen Jan 2014

Antipsychotic Treatment For Children And Adolescents With Schizophrenia Spectrum Disorders: Protocol For A Network Meta-Analysis Of Randomised Trials, A. K. Pagsberg, S. Tarp, D. Glintborg, A. D. Stenstrom, A. Fink-Jensen, Christoph Correll, R. Christensen

Journal Articles

Introduction: Antipsychotic treatment in early-onset schizophrenia (EOS) lacks a rich evidence base, and efforts to rank different drugs concerning their efficacy have not proven any particular drug superior. In contrast to the literature regarding adult-onset schizophrenia (AOS), comparative effectiveness studies in children and adolescents are limited in number and size, and only a few meta-analyses based on conventional methodologies have been conducted. Methods and analyses: We will conduct a network meta-analysis of all randomised controlled trials (RCTs) that evaluate antipsychotic therapies for EOS to determine which compounds are efficacious, and to determine the relative efficacy and safety of these treatments ...